NOACs slow cognitive decline in Alzheimer’s patients with atrial fibrillation
A Karolinska study linked NOAC use to about 0.2 points less annual MMSE decline than warfarin or no anticoagulant.
Key points
From ScienceDaily’s report- Karolinska Institutet study analyzed 7,308 patients with atrial fibrillation and Alzheimer’s.
- Participants were grouped to NOACs, warfarin, or no anticoagulant treatment.
- NOACs slowed MMSE decline by about 0.2 points per year versus others.
- NOACs also linked to lower risks of death, stroke, clots, and fractures.
- Study notes observational design and cannot prove causation; potential confounders exist.
Why it matters. NOACs were also associated with lower risks of death, stroke, clots, and fractures among patients with atrial fibrillation and Alzheimer’s.
What to watch. The observational study cannot prove causation, so further research should assess potential confounders and whether NOACs directly slow cognitive decline.
Coverage
Oldest first · UTCCoverage
Oldest first · UTCSourceScienceDailyUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at ScienceDaily“These blood thinners may have an unexpected benefit for Alzheimer’s patients”
Why it’s in the Brief
Ranked 10th of 10.
- Starting score
- 5.0
- Public-interest topic
- +1.0
- Public-interest terms in the text
- +1.25
- High-reliability sources
- +0.75
- Score
- 8.0
The ranking is the same for everyone.
Perspective mix. 1 center.RatingsAllSides and Media Bias/Fact CheckLean and credibility are curated from their public ratings.Unknown outlets stay unrated, never guessed.